Circ_0061140 Knockdown Inhibits Tumorigenesis and Improves PTX Sensitivity by Regulating MiR-136/CBX2 Axis in Ovarian Cancer

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2021 Oct 15

PMID 34649611

Citations 16

Authors

Jun Zhu

Jun-E Luo

Yurong Chen

Qiong Wu

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian cancer is an aggressive tumor in women with high mortality. Paclitaxel (PTX) can be used for the chemotherapy of ovarian cancer. Here, the roles of circular_0061140 (circ_0061140) in PTX sensitivity and malignant progression of ovarian cancer are unveiled.

Methods: The expressions of circ_0061140, microRNA-136 (miR-136) and chromobox 2 (CBX2) mRNA were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Protein expression was determined by western blot. The half maximal inhibitory concentration (IC) of PTX was determined by 3-(4,5-Dimethylthazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell proliferation was investigated by cell counting kit-8 (CCK-8) and colony formation assays. Cell apoptosis was demonstrated by flow cytometry analysis. Cell migration and invasion were evaluated by transwell assay. The binding relationship between miR-136 and circ_0061140 or CBX2 was predicted by interactome or starbase online database, and identified by dual-luciferase reporter assay. The effects of circ_0061140 on tumor formation and PTX sensitivity in vivo were disclosed by tumor formation assay.

Results: Circ_0061140 and CBX2 expressions were upregulated, while miR-136 expression was downregulated in PTX-resistant tissues and cells compared with control groups. Circ_0061140 knockdown repressed cell proliferation, migration and invasion, and promoted cell apoptosis and PTX sensitivity; however, these effects were restrained by miR-136 RNAi. Additionally, circ_0061140 was a sponge of miR-136, and miR-136 bound to CBX2. Furthermore, circ_0061140 knockdown inhibited tumor formation and improved PTX sensitivity in vivo.

Conclusions: Circ_0061140 silencing repressed the progression and PTX resistance of ovarian cancer by downregulating CBX2 expression via sponging miR-136, which provided novel insight into studying the therapy of ovarian cancer with PTX.

Citing Articles

Interplay of microRNAs and circRNAs in Epithelial Ovarian Cancer.

Schwarzenbach H Noncoding RNA. 2024; 10(5).

PMID: 39452837 PMC: 11510331. DOI: 10.3390/ncrna10050051.

USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2.

Chen J, Shan W, Jia Q, Chen Y, Jiang W, Tian Y Oncogene. 2024; 43(43):3170-3183.

PMID: 39256572 DOI: 10.1038/s41388-024-03151-9.

CBX2 enhances the progression and TMZ chemoresistance of glioma via EZH2-mediated epigenetic silencing of PTEN expression.

Wang J, Yang B, Wang Y, Liu S, Ma C, Piao J Front Pharmacol. 2024; 15:1430891.

PMID: 39114365 PMC: 11303140. DOI: 10.3389/fphar.2024.1430891.

Has_circ_0008285/miR-211-5p/SIRT-1 Axis Suppress Ovarian Cancer Cells Progression.

Elmizadeh K, Homaei A, Bahadoran E, Abbasi F, Moghbelinejad S Int J Mol Cell Med. 2024; 12(4):401-422.

PMID: 39006198 PMC: 11240052. DOI: 10.22088/IJMCM.BUMS.12.4.401.

Deregulated circRNAs in Epithelial Ovarian Cancer With Activity in Preclinical Models: Identification of Targets and New Modalities for Therapeutic Intervention.

Weidle U, Birzele F Cancer Genomics Proteomics. 2024; 21(3):213-237.

PMID: 38670587 PMC: 11059596. DOI: 10.21873/cgp.20442.

References

Li Q, Liu Y, Chen S, Zong Z, Du Y, Sheng X . circ-CSPP1 promotes proliferation, invasion and migration of ovarian cancer cells by acting as a miR-1236-3p sponge. Biomed Pharmacother. 2019; 114:108832. DOI: 10.1016/j.biopha.2019.108832. View

Zheng Q, Bao C, Guo W, Li S, Chen J, Chen B . Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun. 2016; 7:11215. PMC: 4823868. DOI: 10.1038/ncomms11215. View

Liu Y, Chang Y, Cai Y . Hsa_circ_0061140 promotes endometrial carcinoma progression via regulating miR-149-5p/STAT3. Gene. 2020; 745:144625. DOI: 10.1016/j.gene.2020.144625. View

Li J, Fan R, Xiao H . Circ_ZFR contributes to the paclitaxel resistance and progression of non-small cell lung cancer by upregulating KPNA4 through sponging miR-195-5p. Cancer Cell Int. 2021; 21(1):15. PMC: 7788748. DOI: 10.1186/s12935-020-01702-0. View

Gao H, Song X, Kang T, Yan B, Feng L, Gao L . Long noncoding RNA functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. Onco Targets Ther. 2017; 10:205-216. PMC: 5221653. DOI: 10.2147/OTT.S116178. View

Stage T, Bergmann T, Kroetz D . Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review. Clin Pharmacokinet. 2017; 57(1):7-19. PMC: 8572663. DOI: 10.1007/s40262-017-0563-z. View

Zhao H, Liu S, Wang G, Wu X, Ding Y, Guo G . Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer. Oncol Rep. 2014; 33(2):591-8. DOI: 10.3892/or.2014.3640. View

Gil J, OLoghlen A . PRC1 complex diversity: where is it taking us?. Trends Cell Biol. 2014; 24(11):632-41. DOI: 10.1016/j.tcb.2014.06.005. View

Dou Y, Chen F, Lu Y, Qiu H, Zhang H . Effects of Wnt/β-Catenin Signal Pathway Regulated by miR-342-5p Targeting CBX2 on Proliferation, Metastasis and Invasion of Ovarian Cancer Cells. Cancer Manag Res. 2020; 12:3783-3794. PMC: 7247607. DOI: 10.2147/CMAR.S250208. View

10.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

11.

Zhang J, Zhao X, Zhang J, Zheng X, Li F . Circular RNA hsa_circ_0023404 exerts an oncogenic role in cervical cancer through regulating miR-136/TFCP2/YAP pathway. Biochem Biophys Res Commun. 2018; 501(2):428-433. DOI: 10.1016/j.bbrc.2018.05.006. View

12.

Zhang M, Xia B, Xu Y, Zhang Y, Xu J, Lou G . Circular RNA (hsa_circ_0051240) promotes cell proliferation, migration and invasion in ovarian cancer through miR-637/KLK4 axis. Artif Cells Nanomed Biotechnol. 2019; 47(1):1224-1233. DOI: 10.1080/21691401.2019.1593999. View

13.

Liu Y, Guo J, Shen K, Wang R, Chen C, Liao Z . Paclitaxel Suppresses Hepatocellular Carcinoma Tumorigenesis Through Regulating Circ-BIRC6/miR-877-5p/ Axis. Onco Targets Ther. 2020; 13:9377-9388. PMC: 7519811. DOI: 10.2147/OTT.S261700. View

14.

Yang W, Gong P, Yang Y, Yang C, Yang B, Ren L . Circ-ABCB10 Contributes to Paclitaxel Resistance in Breast Cancer Through Let-7a-5p/DUSP7 Axis. Cancer Manag Res. 2020; 12:2327-2337. PMC: 7108723. DOI: 10.2147/CMAR.S238513. View

15.

Chen Q, Zhang J, He Y, Wang Y . hsa_circ_0061140 Knockdown Reverses FOXM1-Mediated Cell Growth and Metastasis in Ovarian Cancer through miR-370 Sponge Activity. Mol Ther Nucleic Acids. 2018; 13:55-63. PMC: 6143755. DOI: 10.1016/j.omtn.2018.08.010. View

16.

Zhao J, Yang T, Li L . LncRNA FOXP4-AS1 Is Involved in Cervical Cancer Progression via Regulating miR-136-5p/CBX4 Axis. Onco Targets Ther. 2020; 13:2347-2355. PMC: 7094166. DOI: 10.2147/OTT.S241818. View

17.

Jangal M, Lebeau B, Witcher M . Beyond EZH2: is the polycomb protein CBX2 an emerging target for anti-cancer therapy?. Expert Opin Ther Targets. 2019; 23(7):565-578. DOI: 10.1080/14728222.2019.1627329. View

18.

Wang S, Zhang G, Zheng W, Xue Q, Wei D, Zheng Y . MiR-454-3p and miR-374b-5p suppress migration and invasion of bladder cancer cells through targetting ZEB2. Biosci Rep. 2018; 38(6). PMC: 6435551. DOI: 10.1042/BSR20181436. View

19.

Zhang N, Jin Y, Hu Q, Cheng S, Wang C, Yang Z . Circular RNA hsa_circ_0078607 suppresses ovarian cancer progression by regulating miR-518a-5p/Fas signaling pathway. J Ovarian Res. 2020; 13(1):64. PMC: 7275507. DOI: 10.1186/s13048-020-00664-1. View

20.

Cao Z, Zhang G, Xie C, Zhou Y . MiR-34b regulates cervical cancer cell proliferation and apoptosis. Artif Cells Nanomed Biotechnol. 2019; 47(1):2042-2047. DOI: 10.1080/21691401.2019.1614013. View